Mylan to sell generic version of Teva oral contraceptive

Mylan will begin US shipments of the contraceptive immediately.

Mylan Inc. (Nasdaq: MYL) partner Family Care Ltd. has obtained US Food and Drug Administration (FDA) approval for its generic version of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) oral contraceptive Nordette. Teva's patent expired some time ago. Mylan will begin US shipments of the contraceptive immediately.

According to IMS Health, brand Nordette had $60.4 million in US sales in the 12 months through September 2012.

Published by Globes [online], Israel business news - www.globes-online.com - on December 30, 2012

© Copyright of Globes Publisher Itonut (1983) Ltd. 2012

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018